More than 1 in 5 people on private insurance pay more $35 a month for insulin. This bill won’t help them.
Category: biotech/medical – Page 1,768
Coin-sized wearable biosensing platform for digital health
A team of researchers in the Faculty of Engineering of The University of Hong Kong (HKU) has developed a coin-sized system that can read weak electrochemical signals and can be used for personalized health monitoring and the measurement of such conditions as diabetes, cardiovascular diseases and mental health. The discovery was featured on the cover of Analytical Chemistry.
The PERfECT System—an acronym for Personalized Electronic Reader for Electrochemical Transistors—is the world’s smallest system of its kind, measuring 1.5 cm x 1.5 cm x 0.2 cm and weighing only 0.4 gram. It is easily wearable, for instance integrated with a smartwatch or as a patch, to allow for continuous monitoring of biosignals such as glucose levels and antibody concentrations in blood and even sweat.
“Our wearable system is tiny, soft and imperceptible to wearers, and it can do continuous monitoring of our body condition. These features mean it has the potential to revolutionize health care technology,” said Dr. Shiming Zhang of the Department of Electrical and Electronic Engineering, who leads the HKU WISE (wearable, intelligent and soft electronics) Research Group to develop the system.
Dr. Katherine High, MD — Gene Therapy Pioneer — President, Therapeutics, Asklepios BioPharmaceutical
Gene therapy pioneer — dr. katherine high, MD — president, therapeutics, askbio.
Dr. Katherine High, MD, is President, Therapeutics, at Asklepios BioPharmaceutical (AskBio — https://www.askbio.com/), where she is also member of the AskBio Board of Directors, and has responsibility for driving the strategic direction and execution of pre-clinical and clinical programs of the company.
AskBio is a wholly owned and independently operated subsidiary of Bayer AG, set up as a fully integrated gene therapy company dedicated to developing life-saving medicines that cure genetic diseases.
Most recently, Dr. High was a Visiting Professor at Rockefeller University and previous to that, she served as President, Head of Research and Development, and a member of the Board of Directors at Spark Therapeutics (a subsidiary of Hoffmann-La Roche), where she directed the development and regulatory approval of Luxturna® (a gene therapy medication for the treatment of the ophthalmic condition Leber congenital amaurosis), and represents the first gene therapy for genetic disease to obtain regulatory approval in both the United States and Europe.
Dr. High was a longtime member of the faculty at the University of Pennsylvania and medical staff at The Children’s Hospital of Philadelphia, where she was also an Investigator of the Howard Hughes Medical Institute. She served a five-year term on the U.S. Food and Drug Administration Advisory Committee on Cell, Tissue and Gene Therapies and is a past president of the American Society of Gene & Cell Therapy.
Futureseek Daily Link Review; 15 August 2022
* FBL67: Jacob Ward – How AI Shapes Our Choices & Bad Habits * Future of funerals? Startup develops ‘holographic conversational video experience’ that allows mourners to have conversations with the dead * Police Used a Baby’s DNA to Investigate Its Father for a Crime.
* The Rise of the Worker Productivity Score * ‘Starbucks fired me for being three minutes late’ * Amazon starts selling private 5G, plants flag on pricing * We Need To Stop Cheerleading Change.
* Breaking Analysis Further defining Supercloud W/ tech leaders VMware, Snowflake, Databricks & others * Thriving in Uncertainty | Shashank Agarwal | TEDx * Why the Space Industry Needs New Role Models | Bianca Cefalo | TEDx.
Study finds that sound plus electrical body stimulation has potential to treat chronic pain
A University of Minnesota Twin Cities-led team has found that electrical stimulation of the body combined with sound activates the brain’s somatosensory or “tactile” cortex, increasing the potential for using the technique to treat chronic pain and other sensory disorders. The researchers tested the non-invasive technique on animals and are planning clinical trials on humans in the near future.
The paper is published in the Journal of Neural Engineering, a highly regarded, peer-reviewed scientific journal for the interdisciplinary field of neural engineering.
During the experiments, the researchers played broadband sound while electrically stimulating different parts of the body in guinea pigs. They found that the combination of the two activated neurons in the brain’s somatosensory cortex, which is responsible for touch and pain sensations throughout the body.